Fairvalue-Calculator Fairvalue-Calculator

Beijing Bohui Innovation Biotechnology Group (300318) Fair Value & Analysis

Healthcare · CN · Market cap 3.7B CNY

Price¥4.45
Fair Value¥7.08
Upside+59.1%
Quality80/100
Evidence: Medium Range ¥5.31 – ¥8.85

Analysis

Beijing Bohui Innovation Biotechnology Group (300318) currently trades at ¥4.45, while our model-based Fair Value estimate is ¥7.08 — implying the stock looks roughly 59.1% undervalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Beijing Bohui Innovation Biotechnology Group Co., Ltd. engages in the research and development, production, sale, and after-sale service of diagnostic products in China. The company offers human immunoglobulin for rabies, tetanus, hepatitis B, and intravenous injections; albumin; human prothrombin complex; and vaccine for rabies. It also provides molecular platform, such as Automatic Real-time Fluorescent Nucleic Acid Cartridge Analyzer(BHQ-III), and GenPlex BHF-VI Nucleic Acid Chip Analyzer; Trace Element Analyzers; Fluorescence Immunoassay Analyzers, and Quantum Dot Analyzer; and detection kits for respiratory, intestinal, reproductive infections, as well as trace element testing, allergen testing, and others. In addition, the company offers mass spectrometers, plate readers, and standardized ion sources; and flash, process, and preparative purification systems. The company was formerly known as Beijing Bohui Innovation Biotechnology Co., Ltd. and changed its name to Beijing Bohui…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Alnylam Pharmaceuticals, Inc (ALNY) -82% Samsung Biologics Co (207940) +9%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.